Literature DB >> 11564491

Role of urotensin II in patients on dialysis.

K Totsune, K Takahashi, Z Arihara, M Sone, F Satoh, S Ito, Y Kimura, H Sasano, O Murakami.   

Abstract

Urotensin II is a potent vasoconstrictor, which also has some vasodilatory properties. We investigated its expression in various tissues and in the plasma of patients with renal dysfunction. Plasma concentrations of urotensin II-like immunoreactivity were 2-fold higher in patients not on dialysis and 3-fold higher in those on haemodialysis thanin healthy individuals. Messenger RNA encoding theurotensin II precursor and the urotensin II receptor precursor were expressed in various human tissues. The peptidemight act as an important regulator in the cardiovascularand renal systems. Urotensin II antagonists could, therefore, be useful in the treatment of diseases affecting theseorgans.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11564491     DOI： 10.1016/S0140-6736(01)06002-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  28 in total

1.  Urotensin-II in systemic sclerosis: a new peptide in pathogenesis.

Authors:  Yavuz Pehlivan; Ahmet Mesut Onat; Gazi Comez; Taner Babacan
Journal:  Clin Rheumatol       Date:  2011-01-28       Impact factor: 2.980

Review 2.  Cardiovascular actions of human urotensin II--considerations for hypertension.

Authors:  Fraser D Russell; Peter Molenaar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

3.  Does cigarette smoking increase plasma urotensin II concentrations?

Authors:  S J Gold; J P Thompson; J P Williams; E E F Helm; J Sadler; W Song; L L Ng; D G Lambert
Journal:  Eur J Clin Pharmacol       Date:  2007-01-25       Impact factor: 2.953

4.  Renal impairment, hypertension and plasma urotensin II.

Authors:  Ari Mosenkis; Radhakrishna R Kallem; Theodore M Danoff; Nambi Aiyar; Jonathan Bazeley; Raymond R Townsend
Journal:  Nephrol Dial Transplant       Date:  2010-07-09       Impact factor: 5.992

5.  Urotensin-II induces ear flushing in rats.

Authors:  J-s Qi; R Schulingkamp; T J Parry; R Colburn; D Stone; B Haertlein; L K Minor; P Andrade-Gordon; B P Damiano
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

6.  In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803).

Authors:  Valeria Camarda; Martina Spagnol; Wei Song; Raffaella Vergura; Adelheid L Roth; Jonathan P Thompson; David J Rowbotham; Remo Guerrini; Erika Marzola; Severo Salvadori; Paolo Cavanni; Domenico Regoli; Stephen A Douglas; David G Lambert; Girolamo Calò
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 7.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

Review 8.  A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects.

Authors:  Benjamin D Hunt; Leong L Ng; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-04-27       Impact factor: 3.000

9.  Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.

Authors:  David J Behm; Stephen M Harrison; Zhaohui Ao; Kristeen Maniscalco; Susan J Pickering; Evelyn V Grau; Tina N Woods; Robert W Coatney; Christopher P A Doe; Robert N Willette; Douglas G Johns; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

10.  No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans.

Authors:  Jonathan T Affolter; David E Newby; Ian B Wilkinson; Matthew J Winter; Richard J Balment; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.